NRx Pharmaceuticals (NRXP) - Imminent Catalyst - 8-K dropped today (follow-up to yesterday's post - I encourage you to check it out). The stock is up nicely this morning, as a result! One of my favorite companies to hold. This company is a winner ... now ... and longer term.
**Key Points:**
* **Read the words I bolded in the 8-K below.** In my opinion, it was completely unnecessary for the FDA reviewer to make this citation. All the excellent documentation/evidence was already provided in the ANDA submission. **To pass this hurdle all that is needed is for the manufacturers of the "vial tip" to sign a certification.** ***C'mon ... really!***
* After KETAFREE is approved, ask yourself why any company would continue to purchase ketamine containing the BZT toxin.
* Remember from yesterday's post, they raised substantial cash very recently and are very prepared for manufacturing the drug. This is huge!
* As stated in the 8-K, the FDA will review the manufacturer certification sign-offs "in the shortest possible review time frame" due to the ketamine shortage.
* **Imminent Catalysts** (in either order):
* **KETAFREE** **approval**
* **NRX-100 NDA submission** (a different formulation of preservative-free IV ketamine than KETAFREE, for psychiatric use)
I have loved this company and its mission since I discovered it. I truly want them to succeed. It has been wonderful to observe their progress and listen to their earnings calls. Their goal is to destigmatize depression of any type (esp. severe) and have a nationwide network of clinics to treat anyone in need (think...military, first responders, victims of assault, and more). They are after treatments that have an immediate positive transformative effect.
# 8-K: [nrxp20260806\_8k.htm](https://www.sec.gov/Archives/edgar/data/1719406/000143774926026428/nrxp20260806_8k.htm)
"As previously disclosed, NRx Pharmaceuticals Inc. (the “Company”) filed an Abbreviated New Drug Application (“ANDA”) for preservative free ketamine in September 2025. The FDA advised the Company on July 30, 2026 of a final determination on first-round review that there were no major deficiencies related to the drug components of the product. The FDA did ask the company to update the label of the product to reflect a labeling change filed by the manufacturer of the Reference Listed Drug (Ketalar®) and identified a major deficiency related to the twist-off cap of the product’s luer lock vial, where an FDA reviewer expressed concern that the vial tip had the potential to deform in clinical use. The FDA sought confirmation that this could not pose a risk to patient safety. The classification as major is required because the matter affects the container closure.
**Management advised the FDA that the luer lock vial has been used in three previously-approved ANDA products and 11.9 million doses of those products have been shipped in the past 12 months without complaints, returns, or recalls. The ANDA contained testing information on 3,500 vials randomly selected from the first 7 manufacturing batches in which the proper function of the luer lock tip was assessed and no defects were observed in any tested vial. The Company additionally provided verification data from an independent reference laboratory documenting that the torque (measured in Newton-Centimeters) required to open the vial was within the design specifications of the product and the three currently-approved ANDA products.**
The FDA granted the Company a clarification meeting that was held on August 6, 2026 to identify the exact information that the Company will be required to provide to address the FDA’s concern about the proper function of the luer lock vial tip. The FDA requested that the company submit certifications from its manufacturer that the preservative-free ketamine ANDA product is manufactured on the same manufacturing lines with the same machinery, plastics, and other characteristics as the three approved ANDA products already in commercial distribution. **This information was included in the ANDA as submitted and will now be supplied to the FDA as signed certifications from the Company’s manufacturers.**
Based on the meeting, the FDA committed to immediately reinitiate review of the ANDA in order to resolve this single identified major deficiency and committed to completing the review in the shortest-possible review cycle. The meeting was attended both by leadership of the Office of Generic Drugs and by Senior Leadership of the FDA Center for Drug Evaluation and Research (CDER). FDA recognized that ketamine is a strategic drug that appears on the current FDA drug shortage list.
NRx management views the completion of a first-round ANDA review with no drug-related major deficiencies as a positive outcome, given that only 14% - 18% of ANDAs are estimated to achieve approval on first-round review. Although no assurances can be given on regulatory determinations, management is optimistic that the identified concern related to packaging will be resolved in a timely manner, consistent with first commercial sales in 2026, given that **FDA has recognized the current drug shortage and lack of U.S.-based supply of ketamine and has committed to completing the review in the shortest possible review time frame.** HHS leadership has identified ketamine as a strategic drug, as have other agencies and departments of the Federal Government."